APR 24, 2026

Medtronic Achieves CE Mark for ApexCut ™ Surgical Blades

April 24, 2026 - Medtronic, a global leader in healthcare technology, today announced CE (Conformité Européenne) mark for ApexCut™ surgical blades, the company's next generation of powered ENT instrumentation designed to improve surgical efficiency[§, 1] and address frequent challenges in the operating room.

Developed in close collaboration with surgeons, ApexCut™ blades are engineered to reduce clogging and deliver smoother, more predictable performance during powered ENT procedures.[§, 1] The blade design incorporates a new mouthpiece and tooth-to-tooth cutting pattern intended to minimize interruptions and help maintain procedural flow. [§, 1]

"We are very excited to receive CE mark for our new ApexCut™ blades for sinus surgery," said Panos Drakoulas, VP of International for the Ear, Nose, and Throat business at Medtronic. "This is a significant milestone that enables us to bring this innovative technology to surgeons across Europe, offering a seamless solution designed to support consistent performance so they can stay focused on what matters most – their patients and the procedure."

CE mark enables initial clinical use across Europe, with first cases expected shortly after approval.

"ApexCut™ blades are a testament to what's possible when we listen to surgeons and innovate with purpose," said Sean Haag, President of the Ear, Nose, and Throat business at Medtronic. "This milestone reflects our commitment to delivering solutions that empower surgeons to provide exceptional care to their patients. We're excited to see the impact this technology will have across Europe and beyond."

About the Ear, Nose, & Throat Business at Medtronic
Medtronic's Ear, Nose, and Throat (ENT) business is the global market leader in ENT, delivering innovative technologies that impact nearly 3 million patients each year. For more than 25 years, we have partnered with physicians to advance care across the specialty. Our portfolio supports surgical procedures related to chronic rhinosinusitis and head and neck cancers, spanning surgical navigation, tissue health, powered instruments, localized drug delivery, intraoperative nerve monitoring, and parathyroid detection. As the global leader in ENT navigation since the introduction of the LandmarX ™ image-guided surgery system in 1998, we continue to advance the field with next-generation platforms including the Stealth AXiS™ Surgical System.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading

global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Marie Gentile
Public Relations
+1-404-693-6028

Ingrid Goldberg
Investor Relations
+1-763-505-2696

Disclaimer
Information contained herein is not medical advice and should not be used as an alternative to speaking with your doctor.
Discuss indications, contraindications, warnings, precautions, adverse events and any further information with your health care professional.
Please note that the intended use of a product may vary depending on geographical approvals.
Medtronic products placed on European markets comply with EU and UK legislation (if applicable) on medical devices.
The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).
Please note that the intended use of a product may vary depending on geographical approvals.
See the device manual(s) for detailed information regarding the intended use, the (implant) procedure, indications, contraindications, warnings, precautions, and potential adverse events.
For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI.
If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com.
Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.
Medtronic products placed on European markets comply with EU andUK legislation (if applicable) on medical devices.

For any further information, contact your local Medtronic representative.

§ Efficiency is defined by the reduction of clogging and minimized interruptions, made possible by the blade's cutting design and FlexMetric™ technology in curved blades that streamline tissue removal and suction flow.

1. Non-clinical testing measuring grams resected prior to first clog, comparing ApexCut blades vs Medtronic Tricut, RAD, and Quadcut blades. REF-32461: D01509297 ApexCut Blade Clog Resistance vs Predicate Sinus Blade Design Characterization Report. Non-clinical testing is not indicative of clinical results.

https://news.medtronic.com/Medtronic-Achieves-CE-Mark-for-ApexCut-TM-Surgical-Blades